| Serial Number | 79408296 |
| Word Mark | AGOMAB |
| Filing Date | Wednesday, September 18, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Thursday, July 31, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 19, 2025 |
| Goods and Services | Pharmaceutical and medical preparations for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; chemical preparations for medical and pharmaceutical purposes, namely, for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; pharmaceutical and medical preparations for use in relation to treating fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; small molecule drugs, namely, medicinal preparations for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; antibodies; pharmaceutical and medical preparations incorporating antibodies for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair |
| Goods and Services | Scientific research and development services; Scientific research in the nature of conducting clinical trials for others; research and development in the fields of fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; research and development in the fields of small molecules and antibodies; research, development and product design of pharmaceutical and medical preparations; pharmaceutical drug development and discovery services; laboratory and medical laboratory product research and development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy, advisory and information services relating to all the aforesaid |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 31, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 31, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | AgomAb Therapeutics NV |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 32 - NOT AVAILABLE |
| Address | BE |
| Event Date | Event Description |
| Thursday, October 31, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, November 4, 2024 | APPLICATION FILING RECEIPT MAILED |
| Friday, January 3, 2025 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, March 17, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, March 19, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, March 20, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, May 5, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, May 5, 2025 | REFUSAL PROCESSED BY MPU |
| Monday, November 4, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, July 3, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, July 3, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, July 3, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, July 11, 2025 | EXAMINERS AMENDMENT E-MAILED |
| Friday, July 11, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Friday, July 11, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, July 15, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 13, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, July 11, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Saturday, May 24, 2025 | REFUSAL PROCESSED BY IB |